Halozyme Therapeutics Ends Pursuit of Evotec

Dow Jones

Nov 22, 2024

By Denny Jacob

Halozyme Therapeutics said it was ending an effort to acquire German drug developer Evotec.

Halozyme Chief Executive Helen Torley said Friday that Evotec has been unwilling to engage with the company on a potential deal, leading the biopharmaceutical company to withdraw its proposal.

San Diego-based Halozyme last week made a non-binding proposal to acquire Evotec for 11 euros a share in cash that put the deal's valuation around 2 billion euros ($2.09 billion). Evotec would go on to confirm the takeover offer.

Shares of Halozyme jumped 12% to $51.32 in premarket trading Friday, while American depositary receipts of Evotec tumbled 14% to $4.60.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

November 22, 2024 09:07 ET (14:07 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2485265254"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2485265254\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2485265254?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-22 22:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485265254","market":"other","top_or_hot":-1,"title":"Halozyme Therapeutics Ends Pursuit of Evotec","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Halozyme <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said it was ending an effort to acquire German drug developer Evotec. \n</p>\n<p>\n  Halozyme Chief Executive Helen Torley said Friday that Evotec has been unwilling to engage with the company on a potential deal, leading the biopharmaceutical company to withdraw its proposal. \n</p>\n<p>\n  San Diego-based Halozyme last week made a non-binding proposal to acquire Evotec for 11 euros a share in cash that put the deal's valuation around 2 billion euros ($2.09 billion). Evotec would go on to confirm the takeover offer. \n</p>\n<p>\n  Shares of Halozyme jumped 12% to $51.32 in premarket trading Friday, while American depositary receipts of Evotec tumbled 14% to $4.60. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 22, 2024 09:07 ET (14:07 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Halozyme Therapeutics Ends Pursuit of Evotec</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHalozyme Therapeutics Ends Pursuit of Evotec\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-11-22 22:07</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Halozyme <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said it was ending an effort to acquire German drug developer Evotec. \n</p>\n<p>\n  Halozyme Chief Executive Helen Torley said Friday that Evotec has been unwilling to engage with the company on a potential deal, leading the biopharmaceutical company to withdraw its proposal. \n</p>\n<p>\n  San Diego-based Halozyme last week made a non-binding proposal to acquire Evotec for 11 euros a share in cash that put the deal's valuation around 2 billion euros ($2.09 billion). Evotec would go on to confirm the takeover offer. \n</p>\n<p>\n  Shares of Halozyme jumped 12% to $51.32 in premarket trading Friday, while American depositary receipts of Evotec tumbled 14% to $4.60. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 22, 2024 09:07 ET (14:07 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HALO","symbol_name":"奥洛兹美医疗","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2485265254","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485265254","pubTimestamp":1732284420,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Halozyme Therapeutics said it was ending an effort to acquire German drug developer Evotec.Halozyme Chief Executive Helen Torley said Friday that Evotec has been unwilling to engage with the company on a potential deal, leading the biopharmaceutical company to withdraw its proposal.San Diego-based Halozyme last week made a non-binding proposal to acquire Evotec for 11 euros a share in cash that put the deal's valuation around 2 billion euros . Evotec would go on to confirm the takeover offer.Shares of Halozyme jumped 12% to $51.32 in premarket trading Friday, while American depositary receipts of Evotec tumbled 14% to $4.60.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HALO":"奥洛兹美医疗","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","BK4139":"生物科技"},"translate_title":"Halozyme Therapeutics结束对Evotec的收购","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HALO":1},"content_text":"By Denny Jacob \n\n\n \n\n\n  Halozyme Therapeutics said it was ending an effort to acquire German drug developer Evotec. \n\n\n  Halozyme Chief Executive Helen Torley said Friday that Evotec has been unwilling to engage with the company on a potential deal, leading the biopharmaceutical company to withdraw its proposal. \n\n\n  San Diego-based Halozyme last week made a non-binding proposal to acquire Evotec for 11 euros a share in cash that put the deal's valuation around 2 billion euros ($2.09 billion). Evotec would go on to confirm the takeover offer. \n\n\n  Shares of Halozyme jumped 12% to $51.32 in premarket trading Friday, while American depositary receipts of Evotec tumbled 14% to $4.60. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 22, 2024 09:07 ET (14:07 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}